P3H4 Promotes Malignant Progression of Lung Adenocarcinoma via Interaction with EGFR

Abstract

Lung cancer is associated with the greatest number of cancer-related deaths worldwide. Lung adenocarcinoma (LUAD) accounts for 85% of all cases of lung cancer. Despite recent advances in treatment, the 5-year survival rate remains less than 15%. Thus, the diagnostic and therapeutic role of LUAD remain to be further studied. The prolyl 3-hydroxylase family member 4 (P3H4) is involved in various cancers, but little is known about its role in LUAD. Our study demonstrated that the P3H4 gene was upregulated in LUAD. Clinically, the expression of P3H4 was positively correlated with an advanced TNM stage and shorter survival. Functionally, P3H4 plays a significant role in the metastasis and proliferation of LUAD both in vitro and in vivo. Mechanistically, P3H4 might interact with EGFR to regulate the metabolic substances. Our study indicated that P3H4 is a critical gene in the malignant progression of LUAD and represents a potential biomarker and therapeutic target.

MIS18A upregulation promotes cell viability, migration and tumor immune evasion in lung adenocarcinoma

“…However, despite recent advances in the diagnosis and treatment of lung cancer, a significant number of patients with LUAD ultimately succumb to the disease. Reports indicate a high mortality rate for LUAD, with a 5-year overall survival (OS) rate of <15% ( 5 , 6 ). Therefore, there is an urgent need to explore novel biomarkers and develop effective therapeutic approaches to improve the diagnosis and prognosis of patients with LUAD.…”